CN101141979B - 猫变应原融合蛋白及其用途 - Google Patents

猫变应原融合蛋白及其用途 Download PDF

Info

Publication number
CN101141979B
CN101141979B CN2006800088726A CN200680008872A CN101141979B CN 101141979 B CN101141979 B CN 101141979B CN 2006800088726 A CN2006800088726 A CN 2006800088726A CN 200680008872 A CN200680008872 A CN 200680008872A CN 101141979 B CN101141979 B CN 101141979B
Authority
CN
China
Prior art keywords
compositions
fel
seq
attachment site
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800088726A
Other languages
English (en)
Chinese (zh)
Other versions
CN101141979A (zh
Inventor
M·巴克曼
M·鲍尔
K·迪特迈尔
N·施米茨
S·尤特津格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytos Biotechnology AG
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Publication of CN101141979A publication Critical patent/CN101141979A/zh
Application granted granted Critical
Publication of CN101141979B publication Critical patent/CN101141979B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2006800088726A 2005-03-18 2006-03-17 猫变应原融合蛋白及其用途 Expired - Fee Related CN101141979B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66291805P 2005-03-18 2005-03-18
US60/662,918 2005-03-18
PCT/EP2006/060845 WO2006097530A2 (en) 2005-03-18 2006-03-17 Cat allergen fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2013101152149A Division CN103203016A (zh) 2005-03-18 2006-03-17 猫变应原融合蛋白及其用途

Publications (2)

Publication Number Publication Date
CN101141979A CN101141979A (zh) 2008-03-12
CN101141979B true CN101141979B (zh) 2013-05-08

Family

ID=36843236

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006800088726A Expired - Fee Related CN101141979B (zh) 2005-03-18 2006-03-17 猫变应原融合蛋白及其用途
CN2013101152149A Pending CN103203016A (zh) 2005-03-18 2006-03-17 猫变应原融合蛋白及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2013101152149A Pending CN103203016A (zh) 2005-03-18 2006-03-17 猫变应原融合蛋白及其用途

Country Status (19)

Country Link
US (3) US7767212B2 (enExample)
EP (1) EP1868642B1 (enExample)
JP (2) JP5302671B2 (enExample)
KR (1) KR20070112225A (enExample)
CN (2) CN101141979B (enExample)
AU (1) AU2006224529B2 (enExample)
BR (1) BRPI0608455A2 (enExample)
CA (1) CA2599218C (enExample)
CY (1) CY1114171T1 (enExample)
DK (1) DK1868642T3 (enExample)
ES (1) ES2424229T3 (enExample)
IL (1) IL185103A0 (enExample)
MX (1) MX2007011160A (enExample)
NZ (1) NZ561040A (enExample)
PL (1) PL1868642T3 (enExample)
PT (1) PT1868642E (enExample)
RU (1) RU2414239C2 (enExample)
WO (1) WO2006097530A2 (enExample)
ZA (1) ZA200707413B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
BR0312792A (pt) * 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
ES2424229T3 (es) * 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
AU2006325225B2 (en) * 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007113633A2 (en) * 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
ES2635870T3 (es) * 2007-07-09 2017-10-05 Nestec S.A. Métodos para reducir las alergias provocadas por alérgenos ambientales
US9388236B2 (en) 2007-07-09 2016-07-12 Nestec Sa Methods for reducing allergies caused by environmental allergens
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
DE112010006063B4 (de) * 2009-11-05 2018-12-27 Novici Biotech Llc Erzeugung von Antigenen, virusartigen Partikeln über Protein-Protein-Bindungen
US8321012B2 (en) 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
EP2794662A1 (en) 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
JO3820B1 (ar) * 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
JP6430949B2 (ja) * 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
EP3036543B1 (en) 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2015092663A1 (en) * 2013-12-19 2015-06-25 Nestec Sa Compositions and methods for reducing cat allergens in the environment
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
WO2016192788A1 (en) * 2015-06-03 2016-12-08 Universität Zürich Prorektorat Mnw Methods and compositions for preventing and treating cat or dog dander allergy
CN108025059B (zh) 2015-09-08 2022-09-09 苏黎世大学 抗猫过敏的组合物
WO2017071713A1 (en) 2015-10-30 2017-05-04 University Of Copenhagen Virus like particle with efficient epitope display
CN105219742A (zh) * 2015-11-10 2016-01-06 海南大学 一种展示重组猫致敏原rFel d 1蛋白的免疫增强型病毒样颗粒、其表达载体及其制备与应用
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
FR3054547B1 (fr) * 2016-07-29 2020-06-05 Angany Inc. Particules pseudo-virales et leurs utilisations
PL3558347T3 (pl) 2016-12-22 2026-04-20 Regeneron Pharmaceuticals, Inc. Sposób leczenia alergii swoistymi dla alergenu przeciwciałami monoklonalnymi
KR20210110318A (ko) 2018-12-20 2021-09-07 사이바 아게 융합에 의해 변형된 cmv의 바이러스-유사 입자
WO2023176206A1 (ja) * 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
CN114933639B (zh) * 2022-05-05 2023-12-29 中国农业科学院兰州兽医研究所 非洲猪瘟病毒p72N抗原表位蛋白及其制备方法和用途
CN117004650B (zh) * 2023-06-25 2024-05-14 山东立菲生物产业有限公司 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用
WO2025139524A1 (zh) * 2023-12-28 2025-07-03 江苏众红生物工程创药研究院有限公司 猫重组变应原及其药用组合物、制备方法和应用
WO2025194374A1 (zh) * 2024-03-20 2025-09-25 深圳赫兹生命科学技术有限公司 猫过敏原多肽片段及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163778A (en) * 1978-05-04 1979-08-07 The Foundation for the Study of Asthma and Related Diseases Asthma immunotherapy
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
DE68924850T2 (de) * 1988-06-14 1996-10-10 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US6120769A (en) * 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
GB9213601D0 (en) * 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
WO1996007428A1 (en) 1994-09-02 1996-03-14 Immulogic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
EP1037663A2 (en) * 1997-12-16 2000-09-27 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
WO2000020032A1 (en) * 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
WO2000023955A1 (en) * 1998-10-21 2000-04-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Virus-like particles for the induction of autoantibodies
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
EP1278542A2 (en) * 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
PL214225B1 (pl) 2000-11-16 2013-07-31 Alk Abello As Zrekombinowany alergen, zastosowanie zrekombinowanego alergenu, kompozycja farmaceutyczna, sposób przygotowania kompozycji farmaceutycznej, sposób przygotowania zrekombinowanego alergenu, sekwencja DNA kodujaca zrekombinowany alergen, wektor ekspresyjny, komórka gospodarza oraz sposób produkcji zrekombinowanego zmutowanego alergenu
EP1221317A1 (en) * 2000-12-28 2002-07-10 SHAN-Beteiligungsgesellschaft m.b.H. Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
DK1219300T3 (da) * 2000-12-28 2007-03-05 Biomay Prod & Handel Behandling af allergi
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
EP1499349B1 (en) 2001-03-02 2009-11-18 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
KR20050044316A (ko) * 2001-11-07 2005-05-12 사이토스 바이오테크놀로지 아게 호산구성 알레르기 질환 치료용의 ｉｌ-5, ｉｌ-13 또는에오탁신을 제시하는 항원 어레이
DE60230656D1 (de) * 2001-11-07 2009-02-12 Cytos Biotechnology Ag Antigenraster welche il-5, il-13 oder eotaxin präshilen erkrankungen
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
RU2325202C2 (ru) 2002-07-19 2008-05-27 Цитос Байотекнолоджи Аг Конъюгаты грелин-носитель
US20060251620A1 (en) * 2002-08-22 2006-11-09 Lidia Ivanova Inducible alphaviral/orip based gene expression system
JP2006520184A (ja) 2002-11-01 2006-09-07 アルカベロ アクチェセルスカプ 組換えタンパク質変種
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
CN101675993A (zh) * 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
DK1620554T3 (da) 2003-04-24 2008-06-02 Imvision Gmbh Rekombinant Fel d 1-allergen
AU2004255470B2 (en) * 2003-07-10 2010-08-19 Cytos Biotechnology Ag Packaged virus-like particles
ES2424229T3 (es) * 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Hans Gronlund et al..Formation of Disulfide Bonds and Homodimers of the Major Cat Allergen Fel d1 Equivalent to the Natural Allergen by Expression in Escherichia coli.THE JOURNAL OF BIOLOGICAL CHEMISTRY.2003,(41),摘要、第40145页左栏第2-3段，图1. *
Lisa D.Vailes et al..High-level expression of immunoreactiverecombinant cat allergen (Fel d 1):Targeting to antigen-presenting cells.J ALLERGY CLIN IMMUNOL.2002,110(5),摘要、第758、761页. *
Liselotte Kaiser et al..The Crystal Structure of the Major Cat Allergen Fel d1,a Member of the Secretoglobin Family.THE JOURNAL OF BIOLOGICAL CHEMISTRY.2003,(39),摘要、第37734页右栏第2段. *
LiselotteKaiseretal..TheCrystalStructureoftheMajorCatAllergenFeld1 a Member of the Secretoglobin Family.THE JOURNAL OF BIOLOGICAL CHEMISTRY.2003
刘春国等.病毒样颗粒技术应用的研究进展.中国预防兽医学报.2005,27(2),第159页2.3节. *

Also Published As

Publication number Publication date
US7767212B2 (en) 2010-08-03
MX2007011160A (es) 2007-11-13
AU2006224529A1 (en) 2006-09-21
RU2414239C2 (ru) 2011-03-20
EP1868642B1 (en) 2013-05-08
NZ561040A (en) 2009-04-30
US20090175896A1 (en) 2009-07-09
ES2424229T3 (es) 2013-09-30
CA2599218C (en) 2015-08-11
RU2007138265A (ru) 2009-04-27
CN101141979A (zh) 2008-03-12
JP5302671B2 (ja) 2013-10-02
CY1114171T1 (el) 2016-08-31
DK1868642T3 (da) 2013-06-24
WO2006097530A3 (en) 2007-06-21
CA2599218A1 (en) 2006-09-21
CN103203016A (zh) 2013-07-17
US20110045013A1 (en) 2011-02-24
WO2006097530A2 (en) 2006-09-21
PL1868642T3 (pl) 2013-10-31
BRPI0608455A2 (pt) 2010-01-05
ZA200707413B (en) 2009-01-28
JP2013155176A (ja) 2013-08-15
PT1868642E (pt) 2013-07-10
AU2006224529B2 (en) 2012-05-24
US20130344098A1 (en) 2013-12-26
EP1868642A2 (en) 2007-12-26
JP2008535800A (ja) 2008-09-04
KR20070112225A (ko) 2007-11-22
IL185103A0 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
EP1868642B1 (en) Cat allergen fusion proteins and uses thereof
US8449874B2 (en) Interleukin-1 muteins linked to virus-like particles to treat IL-1 associated diseases
CN101052411B (zh) Vlp-抗原偶联物及其作为疫苗的用途
US20090123414A1 (en) Il-15 Antigen Arrays And Uses Thereof
CN101951943A (zh) 神经生长因子偶联物及其用途
CA2664418A1 (en) Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
CN101959526A (zh) 白介素-1偶联物在糖尿病治疗中的用途
WO2007039458A2 (en) Hiv peptide conjugates and uses thereof
WO2016192788A1 (en) Methods and compositions for preventing and treating cat or dog dander allergy
AU2013202547A1 (en) Interleukin-1 conjugates and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130508

Termination date: 20150317

EXPY Termination of patent right or utility model